



March 14, 2020

To our valued healthcare providers, patients and other partners,

At Ironwood Pharmaceuticals, we are committed to helping mitigate the spread of COVID-19 and protect the safety and well-being of those around us, including our employees, healthcare providers, patients and broader communities, while striving to ensure that our patients continue to gain access to the medications that they need.

With safety a top priority, Ironwood is asking all our customer-facing employees to suspend personal interactions, including visits to physician offices, clinics and hospitals, through at least March 31 and to provide support virtually. We are focused on doing everything that we can to continue serving you through virtual engagement and will be reaching out to you to discuss how we can meet those needs.

If you have any questions or concerns about any of the products we support, including LINZESS® (linaclotide), or you need to report an adverse event, please contact the appropriate Product Support information line found [here](#).

Thank you for your support during this unprecedented time.

Sincerely,

Mark Mallon
Chief Executive Officer
Ironwood Pharmaceuticals, Inc.